Automated workflows

DDW Editor Reece Armstrong learns about Molecular Devices’ Organoid Innovation Centre (OIC) and how the company is aiming to advance research into 3D biology and organoids.  In April 2021, life sciences solutions provider Molecular Devices launched its Organoid Innovation Centre (OIC), an initiative designed to help scientists leverage the potential of 3D biology throughout the drug discovery […]

Join this BioTek webinar to learn how quantitative phenotypic analysis is central to many zebrafish research workflows. Phenotypic analysis often involves leveraging multiple technologies for molecular, cellular and organismal-level evaluations. Accordin to Biotek, the new Cytation C10 confocal imaging reader is a powerful single-instrument solution for multimodal plate reading, widefield fluorescence microscopy, and spinning disk […]

We know there are operational vulnerabilities in pharmaceutical research and in the drug discovery pipeline. Bringing new drugs to the market is slow and expensive, with high costs, failure rates and cycle times. With low reproducibility and inefficient processes delaying the path to approval, the current pandemic is prompting a fundamental reassessment of strategic priorities. […]

The Covid-19 pandemic has promoted global efforts to develop antiviral treatments against SARS-CoV-2. During this process, the endemic operational vulnerabilities of the drug discovery process have been highlighted. The reality is: bringing new drugs to the market is associated with high costs, high failure rates and long cycle times…and this process is becoming slower and […]

Research laboratories have not fundamentally changed since the 1960s, says BMG LABTECH. Despite improvements in technology such as high-throughput screening and computational drug design, drug discovery is becoming slower and more expensive over time. Covid-19 highlighted operational vulnerabilities which are driving a fundamental reassessment of strategic priorities. In fact, says the company, researchers spend a […]

Covid-19 has highlighted the current operational vulnerabilities in pharmaceutical research and in the drug discovery pipeline. Bringing new drugs to the market is still a slow and expensive process, with far too high costs, failure rates and cycle times. With low reproducibility and inefficient processes delaying the path to approval, the pandemic is prompting a […]